Yuen Yi Ching, Wan Mei Qi, Tan Jun Hao, Chan Noreen
Department of Pharmacy, National University Hospital, Singapore, Singapore.
Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
Eur J Hosp Pharm. 2016 Nov;23(6):331-334. doi: 10.1136/ejhpharm-2015-000834. Epub 2016 Feb 5.
The primary objective of the study was to assess the rationale of fentanyl patch initiation and continuation for pain. The secondary objectives were to analyse prescribing pattern between disciplines, monitoring criteria and adverse events profile of fentanyl patch in the inpatient wards for a tertiary hospital.
A retrospective case series review was undertaken of patients who received transdermal fentanyl for pain from April to June 2013 at the National University Hospital, Singapore. Relevant data were collected from electronic and physical medical records and audit criteria applied for indication, opioid tolerance, dosage regimen, adverse events and monitoring criteria.
40 patients were prescribed fentanyl patches for pain in the study period. 15 patients (62.5%) had one or more problems during initiation of fentanyl patch. Appropriate use during initiation was low with only 9 (38%) patients meeting all the required criteria. Most of the inappropriate use involved a lack of bridging opioids (58%), wrong opioid conversion dose (42%) and use in opioid-naïve patients (42%). In addition, three cases of inappropriate placement were observed. Monitoring for efficacy and adverse effects generally met audit criteria. There was a low incidence of discontinuation (21%) due to its well-tolerated side effect profile.
This study highlighted high incidence of inappropriate initiation of fentanyl patch, and we proposed an in-house guideline to aid physicians in initiating fentanyl patches during admission and to educate nursing staff of the monitoring parameters for efficacy and toxicity.
本研究的主要目的是评估开始和持续使用芬太尼透皮贴剂治疗疼痛的合理性。次要目的是分析一家三级医院住院病房中不同科室之间芬太尼透皮贴剂的处方模式、监测标准及不良事件情况。
对2013年4月至6月在新加坡国立大学医院因疼痛接受透皮芬太尼治疗的患者进行回顾性病例系列研究。从电子和纸质病历中收集相关数据,并应用审核标准评估用药指征、阿片类药物耐受性、给药方案、不良事件及监测标准。
在研究期间,40例患者因疼痛被处方使用芬太尼透皮贴剂。15例患者(62.5%)在开始使用芬太尼透皮贴剂时出现了一个或多个问题。开始使用时的合理用药率较低,只有9例(38%)患者符合所有要求标准。大多数不合理用药情况包括缺乏过渡性阿片类药物(58%)、阿片类药物转换剂量错误(42%)以及在未使用过阿片类药物的患者中使用(42%)。此外,观察到3例贴剂放置不当的情况。疗效和不良反应监测总体符合审核标准。由于其耐受性良好的副作用,停药发生率较低(21%)。
本研究突出了芬太尼透皮贴剂起始使用不当的高发生率,我们提出了一项内部指南,以帮助医生在患者入院时开始使用芬太尼透皮贴剂,并教育护理人员有关疗效和毒性的监测参数。